Your browser doesn't support javascript.
HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019.
Bruni, Laia; Saura-Lázaro, Anna; Montoliu, Alexandra; Brotons, Maria; Alemany, Laia; Diallo, Mamadou Saliou; Afsar, Oya Zeren; LaMontagne, D Scott; Mosina, Liudmila; Contreras, Marcela; Velandia-González, Martha; Pastore, Roberta; Gacic-Dobo, Marta; Bloem, Paul.
  • Bruni L; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP CB06/02/0073), Madrid, Spain. Electronic address: lbruni@iconcologia.net.
  • Saura-Lázaro A; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain. Electronic address: asaura.lazaro@iconcologia.net.
  • Montoliu A; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain. Electronic address: amontoliu@iconcologia.net.
  • Brotons M; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP CB06/02/0073), Madrid, Spain. Electronic address: mbrotons@iconcologia.net.
  • Alemany L; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP CB06/02/0073), Madrid, Spain. Electronic address: lalemany@iconcologia.net.
  • Diallo MS; Data and Analytics Unit, Department of Analysis, Planning & Monitoring, UNICEF, New York, USA. Electronic address: mamsdiallo@unicef.org.
  • Afsar OZ; Maternal, Neonatal & Adolescent Health Unit, Health Section, UNICEF, New York, USA. Electronic address: oafsar@unicef.org.
  • LaMontagne DS; Center for Vaccine Innovation and Access, PATH, Seattle, USA. Electronic address: slamontagne@path.org.
  • Mosina L; Division of Country Health Programmes, Vaccine-preventable Diseases and Immunization (VPI), World Health Organization Regional Office for the Europe, Copenhagen, Denmark. Electronic address: mosinal@who.int.
  • Contreras M; Comprehensive Family Immunization Unit, Pan American Health Organization, PAHO/WHO, Washington, DC, USA. Electronic address: contrermar@paho.org.
  • Velandia-González M; Comprehensive Family Immunization Unit, Pan American Health Organization, PAHO/WHO, Washington, DC, USA. Electronic address: velandiam@paho.org.
  • Pastore R; Division of Country Health Programmes, Vaccine-preventable Diseases and Immunization (VPI), World Health Organization Regional Office for the Europe, Copenhagen, Denmark. Electronic address: pastorero@who.int.
  • Gacic-Dobo M; Immunization Analysis & Insights Vaccines and Biologicals, World Health Organization, Geneva, Switzerland,. Electronic address: gacicdobom@who.int.
  • Bloem P; Life Course and Integration/ EPI, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. Electronic address: bloemp@who.int.
Prev Med ; 144: 106399, 2021 03.
Article in English | MEDLINE | ID: covidwho-1139631
Semantic information from SemMedBD (by NLM)
1. Human Papilloma Virus Vaccine TREATS Malignant tumor of cervix
Subject
Human Papilloma Virus Vaccine
Predicate
TREATS
Object
Malignant tumor of cervix
2. Human Papilloma Virus Vaccine TREATS Malignant tumor of cervix
Subject
Human Papilloma Virus Vaccine
Predicate
TREATS
Object
Malignant tumor of cervix
ABSTRACT
WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 set in the recently approved global strategy for cervical cancer elimination as a public health problem. As of June 2020, 107 (55%) of the 194 WHO Member States have introduced HPV vaccination. The Americas and Europe are by far the WHO regions with the most introductions, 85% and 77% of their countries having already introduced respectively. A record number of introductions was observed in 2019, most of which in low- and middle- income countries (LMIC) where access has been limited. Programs had an average performance coverage of around 67% for the first dose and 53% for the final dose of HPV. LMICs performed on average better than high- income countries for the first dose, but worse for the last dose due to higher dropout. Only 5 (6%) countries achieved coverages with the final dose of more than 90%, 22 countries (21%) achieved coverages of 75% or higher while 35 (40%) had a final dose coverage of 50% or less. When expressed as world population coverage (i.e., weighted by population size), global coverage of the final HPV dose for 2019 is estimated at 15%. There is a long way to go to meet the 2030 elimination target of 90%. In the post-COVID era attention should be paid to maintain the pace of introductions, specially ensuring the most populous countries introduce, and further improving program performance globally.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Papillomavirus Vaccines / COVID-19 Subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Papillomavirus Vaccines / COVID-19 Language: English Journal: Prev Med Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Papillomavirus Vaccines / COVID-19 Subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Papillomavirus Vaccines / COVID-19 Language: English Journal: Prev Med Year: 2021
...